Head-to-head trial reveals better immune-dampening drug for psoriatic arthritis
A newer immune-dampening drug appears to effectively quell pain and swelling in joints affected by psoriatic arthritis, a new study says. The injectable drug bimekizumab (Bimzelx) eased psoriatic arthritis for more patients than a slightly older drug from its same class, risankizumab (Skyrizi), researchers reported at the American College of Rheumatology (ACR) conference in Orlando, Florida.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Unusual pathogen: Fatal viral infection identified during advanced cancer immunotherapy
United Kingdom
-
Clinicians know food allergy panels can lead to overdiagnosis—but order them anyway
United Kingdom
-
Language barriers may keep families from introducing peanuts early
United Kingdom
-
School nurses find stock epinephrine improves safety of students with severe allergies
United Kingdom
-
Wildfire smoke during pregnancy linked to asthma in young children
United Kingdom
-
Patients with meat allergy who take omalizumab may see improvement of symptoms
United Kingdom
-
Small RNA from surrounding cells promotes triple-negative breast cancer growth
United Kingdom
-
Study finds link between eczema and sleep problems in kids
United Kingdom